On September 1, the new chairman of GSK officially took office!

After nearly half a year of searching, GSK's new chairman was finally confirmed On July 24, GSK announced the appointment of Jonathan Symonds, former chief financial officers of Novartis and AstraZeneca, as the next chairman of the board, effective September 1 Jonathan Symonds GSK is facing a huge change in its business Symonds said in a statement that GSK is currently seeking to "create value through innovative research and development methods" and plans to "create and split two new world leading companies", one focusing on pharmaceuticals and vaccines and the other on consumer health The selection of the new chairman also means that Philip Hampton, the current chairman who has held the post since 2015, will officially resign on August 31 In 2014, GSK was charged with political bribery in 10 countries, including China Philip was appointed under the pressure of strong dissatisfaction from shareholders Previously, Philip was the chairman of Royal Bank of Scotland and helped the bank out of its predicament after the financial crisis Philip was appointed as a member of the board of directors on January 1, 2015, vice chairman on April 1, 2015 and chairman on May 7, 2015 Philip was paid £ 700000 in 2017, or about rmb6.13 million Philip's departure this time is also in line with the company's business adjustment from the first split to the second In December 2018, GSK announced that it plans to split its business into two parts The consumer health business will be merged with Pfizer's consumer health business to form a joint venture to be listed separately, with GSK holding 68% and Pfizer holding 32% Jonathan Symonds, currently vice chairman of the board of directors of HSBC, seems to bring important experience in pharmaceutical M & A Symonds has been with AstraZeneca for 10 years and was a competitor to the position of CEO of AstraZeneca He then joined Goldman Sachs and returned to the pharmaceutical industry two years later as chief financial officer of Novartis Some of the most iconic deals AstraZeneca and Roche have made in recent years have been during Jonathan Symonds' tenure Two months before he left, he helped AstraZeneca acquire MedImmune and Novartis acquire the generic drug manufacturer Alcon According to foreign media, Symonds will be paid £ 700000 a year, of which the cash part is £ 525000 and the rest will be settled by GSK shares After taking office, Emma Walmsley, CEO of GSK, continued to promote the divestiture of non core businesses At the end of 2018, GSK announced to sell its Horlicks nutrition business of consumer health sector to Unilever for us $3.8 billion to raise funds for the acquisition of tesaro project investment GSK then announced that it would split its business into pharmaceutical and vaccine and consumer health, and that the consumer health business would merge with Pfizer's consumer health business to form a joint venture At present, reform seems to be the right choice On Wednesday, GSK announced its results for the second quarter of 2019, achieving a turnover of £ 7.81 billion, a year-on-year increase of 6.8%, exceeding the average expectation of £ 7.59 billion; net profit of £ 964 million, a year-on-year increase of 119%; adjusted earnings per share of 30.5p, higher than the market expectation of 25.18p Reference source: with Pharma consumer split in its signals, GSK hands chair seat to symbols